Prognostic Impact of Mucin Expression in Curatively Resected Ampulla of Vater Cancer
Author:
Noh Byeong Gwan1ORCID, Seo Hyung Il1ORCID, Park Young Mok1, Song Su-Bin1ORCID, Kim Suk2, Hong Seung Baek2, Lee Nam Kyung2, Lee Jonghyun3ORCID, Kim Tae In3ORCID, Kwon Chae Hwa4, Ahn Ji Hyun5
Affiliation:
1. Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea 2. Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea 3. Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea 4. Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea 5. Department of Pathology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea
Abstract
Introduction: Mucins play a pivotal role in epithelial carcinogenesis; however, their role remains elusive in ampulla of Vater (AoV) cancer, regardless of histological subtype. Therefore, we investigated the clinical significance of MUC1, MUC2, MUC5AC, and MUC6 expression in AoV cancer. Methods: Using samples from 68 patients with AoV cancer, we performed immunohistochemical staining for MUC1, MUC2, MUC5AC, and MUC6 using a tissue microarray. Subsequently, we analyzed their expression patterns in relation to clinicopathological parameters and patient outcomes. Results: Of the patients, 98.5% exhibited positive expression for MUC1, while MUC2, MUC5AC, and MUC6 were expressed in 44.1%, 47.1%, and 41.2% of the patients, respectively. Correlation analyses between mucin expression and clinicopathological factors revealed no significant associations, except between MUC5AC expression and N stage. Univariate analysis demonstrated significant associations between MUC5AC expression and overall survival (OS). Multivariate analysis further confirmed that MUC5AC expression was a significant predictor of OS, along with the N stage. However, MUC5AC expression was not meaningfully associated with recurrence-free survival (RFS). The patients positive for MUC5AC expression had a considerably shorter OS than those with negative expression. Conclusions: Our study provides insights into the clinical impact of mucins on AoV cancer, regardless of the histological subtype. Although MUC1 expression is universal, MUC5AC expression is a significant prognostic indicator that correlates with lymph node metastasis and poor OS. These results emphasize the possible utility of MUC5AC as a biomarker for extensive lymph node dissection and the prognostic evaluation of patients with AoV cancer.
Funder
Pusan National University Hospital
Reference30 articles.
1. Morita, S.Y., Balch, C.M., Klimberg, V.S., Pawlik, T.M., Posner, M.C., and Tanabe, K.K. (2018). Textbook of Complex General Surgical Oncology, McGraw-Hill Education. 2. Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: S surveillance, epidemiology, and end results (SEER) cohort study;Ramai;Minerva Gastroenterol. Dietol.,2019 3. Ampullary region carcinomas: Definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases;Adsay;Am. J. Surg. Pathol.,2012 4. Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: A retrospective study of 5-year survivors;Ezzat;Hepatobiliary Pancreat. Dis. Int.,2018 5. Bronsert, P., Kohler, I., Werner, M., Makowiec, F., Kuesters, S., Hoeppner, J., Hopt, U.T., Keck, T., Bausch, D., and Wellner, U.F. (2013). Intestinal-type of differentiation predicts favourable overall survival: Confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and du-odenal origin. BMC Cancer, 13.
|
|